EGFR and non-small cell lung carcinoma: Accordingly, overcoming T790M/C797S has emerged as the modern challenge in advancing treatments in EGFR NSCLC; ongoing drug discovery efforts are needed to advance more effective agents [30, 31, 32, 33, 34].